Funded Projects › H2020
CARDIOCARE · AN INTERDISCIPLINARY APPROACH FOR THE MANAGEMENT OF THE ELDERLY MULTIMORBID PATIENT WITH BREAST CANCER THERAPY INDUCED CARDIAC TOXICITY
More than 50% of the newly diagnosed breast cancer patients are elderly and particularly susceptible to cardiotoxicity of cancer treatment due to age-related factors and prevalence of multiple co-morbidities. The cumulative effect of risk factors in the elderly patient resembles a “snowball effect”, where baseline age and cancer-related changes are exacerbated by direct therapy-induced cardiotoxicity, resulting to a multi-morbid state and mortality. Frailty and high risk of cardiotoxicity in this group may lead to inappropriate interventions and undertreatment, resulting in poorer outcomes, deterioration of QoL and increased healthcare costs. Considering, that older cancer patients are underrepresented in trials, new interdisciplinary and patient-oriented studies able to provide clinical guidelines and best practices for delivering quality care are needed. CARDIOCARE will contribute to scale up a better management for the multimorbid elderly breast cancer patients. Innovative eHealth applications, coupled with sensors and wearables, will permit a consistent evaluation of the intrinsic capacity and by combining clinical and biological features, will provide a holistic approach to the management of cancer and his co-morbidities in the elderly population. This will allow the development of quality indicators for effective care pathways and allow a more informed approach to breast cancer patients with multimorbidity, training and education of caregivers and stakeholders to boost effectively elderly breast cancer patients along disease trajectory and cardiotoxicity. eHealth applications will increase the involvement and participation of the patients in their care process and self-management improving adherence to their individualized care plan, and a better psychological adaptation to their disease. Overall, the implementation of a comprehensive model for effective risk stratification will positively impact on QoL, adverse events, hospitalizations, and healthcare.
Consortium · 12 organisations
PANEPISTIMIO IOANNINON
EL · €1,290,000
OGKOLOGIKO KENTRO TRAPEZAS KYPROU
CY · €578,000
ISTITUTO EUROPEO DI ONCOLOGIA SRL
IT · €519,000
ETHNIKO KAI KAPODISTRIAKO PANEPISTIMIO ATHINON
EL · €675,000
SOCIETE EUROPEENNE DE CARDIOLOGIE
FR · €183,794
IDRYMA TECHNOLOGIAS KAI EREVNAS
EL · €314,875
I.M.S. - ISTITUTO DI MANAGEMENT SANITARIO SRL
IT · €239,375
ONKOLOSKI INSTITUT LJUBLJANA
SI · €251,000
PHILIPS ELECTRONICS NEDERLAND BV
NL · €700,250
REGION STOCKHOLM
SE · €285,588
STREMBLE VENTURES LTD
CY · €652,500
ELLINIKO MESOGEIAKO PANEPISTIMIO
EL · €307,250
Research fields
← Find collaborators and more funded projects
Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.